FDA Cracks Down on “Bad Actors” in Dietary Supplement Market

The agency sends warning letters to makers of products that claim to prevent or treat Alzheimer’s and other diseases, and announces changes to its enforcement practices.

Written byShawna Williams
| 2 min read
pill bottles and pills on a wooden table

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, XB100

The US Food and Drug Administration yesterday (February 11) announced it was posting warning or advisory letters about 17 companies for marketing dozens of products it deems “unapproved new drugs and/or misbranded drugs.” The agency also released a lengthy statement by FDA Commissioner Scott Gottlieb on new steps “to protect the public from unsafe and unlawful products” and penalize bad actors in the dietary supplement marketplace.

Gottlieb’s statement notes that in the quarter-century since Congress passed the law that gives the FDA the authority to regulate the dietary supplement industry, that market has grown from offering about 4,000 products to between 50,000 and 80,000, and that three out of four Americans now consume supplements regularly. “As the popularity of supplements has grown, so have the number of entities marketing potentially dangerous products or making unproven or misleading claims about the health benefits they may deliver,” the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies